Anti-STAT3 antibody [EPR787Y] (Ab68153)
APRF, STAT3, Signal transducer and activator of transcription 3, Acute-phase response factor
详细信息
背景信息
Product Specifications Anti-STAT3 antibody [EPR787Y] (ab68153) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ChIC/CUT&RUN-seq, Flow Cyt (Intra), ICC/IF, IHC-P, WB in human, mouse, rat samples. Anti-STAT3 antibody [EPR787Y] (ab68153) specifically detects STAT3 (UniProt ID: P40763; Molecular weight: 88kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-STAT3 antibody [EPR787Y] (ab68153) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-STAT3 antibody [EPR787Y] (ab68153) has been confirmed by testing in knockout samples. Anti-STAT3 antibody [EPR787Y] (ab68153) has been cited over 352 times in peer reviewed journals and is trusted by the scientific community. Anti-STAT3 antibody [EPR787Y] (ab68153) has 10 independent reviews from customers. Related Products Conjugation-ready, carrier free format available for antibody clone EPR787Y - ab232558. Antibody clone EPR787Y is also available pre-conjugated to a variety of labels for your convenience - HRP, Alexa Fluor® 647 ( ab194307, ab300101 ). Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (543)
Tumour-infiltrating microplastics disrupt the JAK-STAT-microbiota axis to promote immunotherapy resistance in colorectal cancer.
肿瘤浸润性微塑料会破坏 JAK-STAT-微生物群轴,从而促进结直肠癌的免疫治疗耐药性。
Aminated fullerene-based nanoplatform enables synergistic VEGFR2-targeted anti-angiogenesis and tumor immunotherapy.
基于氨基化富勒烯的纳米平台可实现协同的 VEGFR2 靶向抗血管生成和肿瘤免疫治疗。
Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis.
单细胞多组学揭示了驱动肺纤维化的内皮机械敏感性 PIEZO1-IL-33 轴。
Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.
发现并鉴定出信号素 4D 作为血糖控制良好的 2 型糖尿病小鼠骨折发生率高的生物标志物。
f-SPION-mediated magnetic stimulation induces reparative Schwann cell reprogramming via cytoskeletal dynamics - gated activation of Piezo1.
f-SPION介导的磁刺激通过细胞骨架动力学门控激活Piezo1诱导修复性雪旺细胞重编程。
Methylated circPTK2 as a driver of fibroblast activation in pulmonary fibrosis.
甲基化的 circPTK2 是肺纤维化中成纤维细胞活化的驱动因素。
Astrocytic GSTM2-STAT3 interaction ameliorates the diabetes associated cognitive dysfunction via targeting mitochondrial defects and oxidative stress.
星形胶质细胞 GSTM2-STAT3 相互作用通过靶向线粒体缺陷和氧化应激来改善糖尿病相关的认知功能障碍。
Co-delivery of panobinostat and siSTAT3 using engineered M1 exosomes to establish a one-two punch therapeutic strategy for glioblastoma recurrence.
利用工程化的 M1 外泌体共同递送帕比司他和 siSTAT3,建立治疗胶质母细胞瘤复发的双重打击疗法。
Coordinated DNA methyltransferase 3A and methyltransferase-like 7A activity reprograms the tumor microenvironment through discoidin domain receptor 1 signaling.
DNA甲基转移酶3A和甲基转移酶样7A的协同活性通过盘状结构域受体1信号传导重编程肿瘤微环境。
ISG15-driven immune modulation and tumor progression in breast cancer metastasis: insights from single-cell and spatial transcriptomics.
ISG15 驱动的免疫调节和乳腺癌转移中的肿瘤进展:来自单细胞和空间转录组学的见解。
- 1
- 2
- 3
- 4
- 5
- 6
- 55